Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.

Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect® self-pay pharmacy channel.

Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose vials of blockbuster obesity drug Zepbound.Ro said Wednesday that it integrated its technology with Lilly’s direct-to-consumer service LillyDirect so that patients can talk to a doctor,

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.

Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials through telehealth platform Ro. The vials will be made available through an integration with Lilly’s (LLY) LillyDirect self-pay pharmacy channel.